Ariad Pharma: Advancing Ahead of Phase 3 Interim Results Print E-mail
Wednesday, 29 July 2009 08:58

The Lucky 13 Buys portfolio continues to advance. In the past two sessions, some of the companies have seen a dramatic rise in their share prices.  View the results from Friday, July 24 in this article. As of the close on Tuesday, July 28, four companies are up over 30%.  While seven of the 13 have achieved gains exceeding 20%, nine are above 10%.

 

 

Symbol

Last/NAV

%Gain/Loss

ARIA

2.80

85.43%

ONTY

4.40

37.07%

SUPG

2.70

33.00%

GTXI

10.58

30.46%

FSYS

23.98

28.79%

SWC

6.39

26.04%

ONB

11.33

20.92%

SPPI

6.75

19.89%

PRXL

14.44

14.33%

UNG

12.90

5.91%

TOMO

2.78

5.30%

CLNE

8.94

3.83%

OSIR

12.70

1.36%

 

Data is based on the closing prices on Tuesday July 7 to Tuesday July 27, 2009.

 

 

Ariad Pharmaceuticals (Nasdaq: ARIA) shares jumped following a significant Phase 1 clinical trial announcement and in front of much anticipated interim phase 3 results for the company’s cancer drug, ridaforolimus.  An announcement is due any day.  ARIA will report quarterly earnings on Thursday, July 30 at 4:15 PM ET.  Investors can access the webcast here.

 

Spectrum Pharmaceuticals (Nasdaq: SPPI) continues its climb as investors anticipate the company’s two cancer drugs, Zevalin and Fusilev, will be approved on or before September 7 and October 8, 2009, respectively.

 

Old National Bank (NYSE: ONB) rose early this week on a positive quarterly earnings announcement.

 

 

Disclosure: Long ARIA and SPPI




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter